Akros SCHK HK-Korea Cosmetics Index

Q2 2026 earnings release is scheduled.

2Q 2026 earnings release on 2026-07-29; analysts forecast a significant profit increase due to the recognition of a large, one-time technology export contract fee. High importance is estimated due to the expected >10% price impact from the revenue surge, forecasted and scheduled.

Q2 2026 earnings release scheduled. Analysts forecast revenue of 1.322 trillion KRW and operating profit of 599.7 billion KRW. High importance is estimated due to the significant growth forecast likely resulting in a >=10% price impact, scheduled.

Partner Johnson & Johnson announced that Q2 2026 global sales of the Leclaza (lazertinib) combination therapy increased by 60.8% year-over-year to $289 million, signaling a rise in royalty income for Yuhan; estimated >5% price impact due to significant revenue growth, expected.

HLB announced that the FDA's manufacturing site issue for its liver cancer drug was resolved with a 'Voluntary Action Indicated' (VAI) classification, causing a 30% stock price surge.

Announced a joint research project with SK Telecom that successfully used AI to discover initial active substances for anti-cancer drugs, shortening the typical research period from 1-2 years to about 5 months.

Celltrion received IND approval from the Korean Ministry of Food and Drug Safety on 2026-07-15 to begin a Phase 1 clinical trial for CT-P68. Low importance is estimated as Phase 1 approvals for biosimilars typically result in a price impact of 1-5%.

Celltrion voluntarily withdrew its European clinical trial plan for 'CT-P51' on 2026-07-14. Low importance is estimated as this strategic decision to align with regulatory trends is expected to have a minimal market impact of 1-5%.